Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Nephrology Drugs Market Grown from 2024 to 2025?

The market for nephrology drugs has seen substantial growth in recent years, and its size is projected to expand from $16.88 billion in 2024 to $17.86 billion in 2025, a compound annual growth rate (CAGR) of 5.8%. The historical growth in this sector can be credited to a number of factors, including an increase in the prevalence of chronic kidney diseases (CKD), advancements in the process of drug development, increased public awareness and medical diagnoses, government efforts, and amendments to healthcare policies, as well as a rising incidence associated with diabetes.

What Growth Rate Is Anticipated for the Nephrology Drugs Market in the Coming Years?

The market size for nephrology drugs is projected to experience significant expansion in the upcoming years, reaching “$23.04 billion by 2029, with a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period can be accredited to factors such as the development of new therapies and drug innovations, the rise of precision medicine and tailor-made treatment methods, an increase in healthcare spending, the introduction of telehealth and remote patient observation, along with global health initiatives. Noteworthy trends anticipated within the forecast period encompass collaborations and partnerships, technological progress in dialysis, advancements in treatment methods, a growing focus on early diagnosis and intervention, and the incorporation of technology in nephrology management.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

Who Are the Leading Companies in the Nephrology Drugs Market?

Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

What Are the Key Drivers of the Nephrology Drugs Market?

The increasing incidence of chronic kidney disease is anticipated to spur the expansion of the nephrology drugs market. Chronic kidney disease (CKD) involves weakened kidneys that are unable to efficiently purify the blood; because this damage develops over a long period, harmful waste can build up in the body. Nephrology medications are mainly used to improve kidney function and slow the progress of CKD, thus preventing additional damage to the body. This positively affects the growth of the nephrology drug market. For example, data shared in July 2022 by the Centers for Disease Control and Prevention (CDC), a health protection agency based in the U.S., revealed that more than 37 million individuals in the U.S. were diagnosed with CKD, most prevalently among those aged 65 or older (38 percent). Furthermore, the Kidney Foundation of Canada, a non-profit organization, states that 4 million Canadians have kidney diseases, with diabetes accounting for 35 percent of kidney failure cases. These figures are projected to increase in the future. Hence, the mounting incidence of chronic kidney disease is fuelling the expansion of the nephrology drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp

What Are the Key Market Segments in the Nephrology Drugs Industry?

The nephrology drugs market covered in this report is segmented –

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)

2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa

3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics

4) By ACE Inhibitors: Lisinopril, Enalapril

5) By Antidiabetic Agents: Metformin, Insulin

6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

What Are the Latest Trends in the Nephrology Drugs Market?

Product innovation is emerging as a crucial trend within the nephrology drug market. To maintain their footing in the market, leading companies are investing in the development and creation of new products and drugs. For instance, in March 2022, Indian pharmaceutical firm Zydus Lifesciences Limited unveiled Oxemia (desidustat) for the treatment of chronic kidney disease (CKD). As an oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, Oxemia offers a convenient therapeutic solution for treating anemia and it passed the Phase III clinical trials with approval from the Drug Controller General of India. The trials demonstrated promising results, including safe profiles, hepcidin lowering, improved iron movement, and lessened LDL-C in CKD patients. Importantly, this treatment is affordable and aims to enhance patients’ quality of life and reduce the impact of the disease.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

What Are the Key Regional Markets in the Nephrology Drugs Industry?

North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076

This Report Delivers Insight On:

1. How big is the nephrology drugs market, and how is it changing globally?

2. Who are the major companies in the nephrology drugs market, and how are they performing?

3. What are the key opportunities and risks in the nephrology drugs market right now?

4. Which products or customer segments are growing the most in the nephrology drugs market?

5. What factors are helping or slowing down the growth of the nephrology drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model